Depósito Académico >
Facultad de Medicina >
Departamento de Anatomía >
DA - Medicina - Anatomía - Artículos de revista >
|Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease.|
|Authors: ||Cuadrado-Tejedor, M. (Mar)|
Garcia-Osta, A. (Ana)
Ricobaraza, A. (Ana)
Oyarzabal, J. (J.)
Franco, R. (Rafael)
|Keywords: ||Alzheimer's disease|
amyloid and Tau
|Issue Date: ||2011|
|Publisher: ||Bentham Science Publ LTD|
|Citation: ||Cuadrado-Tejedor M, Garcia-Osta A, Ricobaraza A, Oyarzabal J, Franco R. Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease. Curr Med Chem 2011;18(36):5545-5553.|
4-phenylbutyrate (PBA) is a small molecule that restores cognitive deficits in animal models of Alzheimer's disease (AD). Although the molecular basis of the cognitive benefits of PBA remains unknown, a multi-modal/multi-target mechanism has been proposed. Putative targets of this drug are different from those of drugs that are now used in clinical trials. As PBA is already administered to patients with congenital defects affecting enzymes in the urea cycle, it can be rapidly tested in AD clinical trials. However, the main drawback to its therapeutic use is the high dosage required (up to 15 g/day). Thus, deciphering the precise mechanism(s) of action of this drug may enable novel drugs with similar therapeutic effects to PBA to be developed that can be used at more manageable doses.
|Permanent link: ||http://hdl.handle.net/10171/23299|
|Appears in Collections:||DA - Medicina - Anatomía - Artículos de revista|
|Files in This Item:|
There are no files associated with this item.
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.